fluvoxamine extended-release / Generic mfg. - LARVOL DELTA

[VIRTUAL] Role of Newer Antidepressants in Social Anxiety Disorder (SAD) (CPNP 2021) - "The 1-year prevalence rate for anxiety disorders is 21.3% in persons aged 18 years and older, and the 1-year prevalence of social anxiety disorder (SAD) specifically is 8.0%.First-line agents for the treatment of SAD include selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitor antidepressants, specifically escitalopram, fluvoxamine controlled-release, paroxetine, sertraline, and venlafaxine extended-release. Only a few studies analyzing the use of newer antidepressants such as vilazodone, levomilnacipran, and vortioxetine have been published...In addition, a literature search on the topic revealed only a few clinical trials evaluating newer antidepressants for the treatment of SAD. Learning Objectives: Evaluate a patient for social anxiety disorder using validated screening tools.Compare the efficacy and/or adverse effects of current treatment options for social anxiety disorder.Assess the role of newer antidepressants in the treatment..."

Cardiovascular • CNS Disorders • Depression • Gastrointestinal Disorder • Major Depressive Disorder • Mental Retardation • Mood Disorders • Psychiatry • Respiratory Diseases • Social Anxiety Disorder • Substance Abuse

Combined fluvoxamine and extended-release methylphenidate improved treatment response compared to fluvoxamine alone in patients with treatment-refractory obsessive-compulsive disorder: A randomized double-blind, placebo-controlled study. (PubMed, Eur Neuropsychopharmacol) - "In summary, combined treatment with MPH-ER demonstrated an enhanced clinical rate of response compared to placebo. Further trials should examine MPH-ER efficacy in a larger sample."

Clinical • Journal